Human Genome Epidemiology Literature Finder
|
Records 1 - 30 (of 44 Records) |
| Query Trace: Disease and BID[original query] |
|---|
| A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecologic oncology 2015 Jun 137 (3): 386-91. Coleman Robert L, Sill Michael W, Bell-McGuinn Katherine, Aghajanian Carol, Gray Heidi J, Tewari Krishnansu S, Rubin Steven C, Rutherford Thomas J, Chan John K, Chen Alice, Swisher Elizabeth |
| A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). European journal of cancer (Oxford, England : 1990) 2015 Dec 54 11-17. Flinn Ian W, Bartlett Nancy L, Blum Kristie A, Ardeshna Kirit M, LaCasce Ann S, Flowers Christopher R, Shustov Andrei R, Thress Kenneth S, Mitchell Patrick, Zheng Fred, Skolnik Jeffrey M, Friedberg Jonathan |
| Association of BID SNPs (rs8190315 and rs2072392) and clinical features of benign prostate hyperplasia in Korean population. Journal of exercise rehabilitation 2014 Dec 10 (6): 383-8. Seok Hosik, Kim Su Kang, Yoo Koo Han, Lee Byung-Cheol, Kim Young Ock, Chung Joo- |
| Correlation of hypertension and proteinuria with outcome in elderly bevacizumab-treated patients with metastatic colorectal cancer. PloS one 2015 1 10 (1): e0116527. Feliu Jaime, Salud Antonieta, Safont Maria J, García-Girón Carlos, Aparicio Jorge, Losa Ferran, Bosch Carlos, Escudero Pilar, Casado Enrique, Jorge Monica, Bohn Uriel, Pérez-Carrión Ramon, Carmona Alberto, Custodio Ana B, Maurel Jo |
| GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. Journal of translational medicine 2016 14 (1): 125. Pietrantonio Filippo, Berenato Rosa, Maggi Claudia, Caporale Marta, Milione Massimo, Perrone Federica, Tamborini Elena, Baratti Dario, Kusamura Shigeki, Mariani Luigi, Niger Monica, Mennitto Alessia, Gloghini Annunziata, Bossi Ilaria, Settanni Giulio, Busico Adele, Bagnoli Pietro Francesco, Di Bartolomeo Maria, Deraco Marcello, de Braud Filip |
| Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecologic oncology 2015 Dec . Domchek Susan M, Aghajanian Carol, Shapira-Frommer Ronnie, Schmutzler Rita K, Audeh M William, Friedlander Michael, Balmaña Judith, Mitchell Gillian, Fried Georgeta, Stemmer Salomon M, Hubert Ayala, Rosengarten Ora, Loman Niklas, Robertson Jane D, Mann Helen, Kaufman Bel |
| Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer. Clinical breast cancer 2017 9 18 (1): e135-e142. Anampa Jesus, Chen Alice, Wright John, Patel Margi, Pellegrino Christine, Fehn Karen, Sparano Joseph A, Andreopoulou Ele |
| Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. The journal of prevention of Alzheimer's disease 2017 4 (3): 149-156. Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, Gauthier S, Hey J A, Power A, Wang P, Shen L, Tolar |
| SELECT-2: a phase II, double-blind, randomized, placebo-controlled study to assess the efficacy of selumetinib plus docetaxel as a second-line treatment of patients with advanced or metastatic non-small-cell lung cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2017 10 28 (12): 3028-3036. Soria J-C, Fülöp A, Maciel C, Fischer J R, Girotto G, Lago S, Smit E, Ostoros G, Eberhardt W E E, Lishkovska P, Lovick S, Mariani G, McKeown A, Kilgour E, Smith P, Bowen K, Kohlmann A, Carlile D J, Jänne P |
| A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours. British journal of cancer 2018 12 120 (3): 286-293. de Weger Vincent A, de Jonge Maja, Langenberg Marlies H G, Schellens Jan H M, Lolkema Martijn, Varga Andrea, Demers Brigitte, Thomas Koruth, Hsu Karl, Tuffal Gilles, Goodstal Samantha, Macé Sandrine, Deutsch Er |
| A phase 1 study of PARP-inhibitor ABT-767 in advanced solid tumors with BRCA1/2 mutations and high-grade serous ovarian, fallopian tube, or primary peritoneal cancer. Investigational new drugs 2018 1 36 (5): 828-835. van der Biessen Diane A J, Gietema Jourik A, de Jonge Maja J A, Desar Ingrid M E, den Hollander Martha W, Dudley Matthew, Dunbar Martin, Hetman Robert, Serpenti Camille, Xiong Hao, Mittapalli Rajendar K, Timms Kirsten M, Ansell Peter, Ratajczak Christine K, Shepherd Stacie Peacock, van Herpen Carla M |
| Phase 1 Dose Escalation Study of the Allosteric AKT Inhibitor BAY 1125976 in Advanced Solid Cancer-Lack of Association between Activating AKT Mutation and AKT Inhibition-Derived Efficacy. Cancers 2019 12 11 (12): . Schneeweiss Andreas, Hess Dagmar, Joerger Markus, Varga Andrea, Moulder Stacy, Tsimberidou Apostolia M, Ma Cynthia, Hurvitz Sara A, Rentzsch Christine, Rudolph Marion, Thiele Silke, Boix Oliver, Wilkinson Gary, Lagkadinou Eleni, Ocker Matthi |
| OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Annals of oncology : official journal of the European Society for Medical Oncology 2019 1 30 (4): 558-566. Robson M E, Tung N, Conte P, Im S-A, Senkus E, Xu B, Masuda N, Delaloge S, Li W, Armstrong A, Wu W, Goessl C, Runswick S, Domchek S |
| Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. BMC cancer 2020 8 20 (1): 760. Jiang Haiping, Zheng Yulong, Qian Jiong, Mao Chenyu, Xu Xin, Li Ning, Xiao Cheng, Wang Huan, Teng Lisong, Zhou Hui, Wang Shuyan, Zhu Donglei, Peng Bo, Shen Lin, Xu No |
| Phase I Study of Afatinib and Selumetinib in Patients with KRAS-Mutated Colorectal, Non-Small Cell Lung, and Pancreatic Cancer. The oncologist 2020 12 26 (4): 290-e545. van Brummelen Emilie M J, Huijberts Sanne, van Herpen Carla, Desar Ingrid, Opdam Frans, van Geel Robin, Marchetti Serena, Steeghs Neeltje, Monkhorst Kim, Thijssen Bas, Rosing Hilde, Huitema Alwin, Beijnen Jos, Bernards Rene, Schellens J |
| Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study). ESMO open 2021 7 6 (4): 100212. Perez-Fidalgo J A, Cortés A, Guerra E, García Y, Iglesias M, Bohn Sarmiento U, Calvo García E, Manso Sánchez L, Santaballa A, Oaknin A, Redondo A, Rubio M J, González-Martín |
| A phase I study of binimetinib (MEK 162), a MEK inhibitor, plus carboplatin and pemetrexed chemotherapy in non-squamous non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2021 5 157 21-29. Fung A S, Graham D M, Chen E X, Stockley T L, Zhang T, Le L W, Albaba H, Pisters K M, Bradbury P A, Trinkaus M, Chan M, Arif S, Zurawska U, Rothenstein J, Zawisza D, Effendi S, Gill S, Sawczak M, Law J H, Leighl N |
| Phase 1 cohort expansion study of LY3023414, a dual PI3K/mTOR inhibitor, in patients with advanced mesothelioma. Investigational new drugs 2021 Mar . Zauderer Marjorie G, Alley Evan W, Bendell Johanna, Capelletto Enrica, Bauer Todd M, Callies Sophie, Szpurka Anna M, Kang Suhyun, Willard Melinda D, Wacheck Volker, Varghese Anna |
| A phase I dose-finding, pharmacokinetics and genotyping study of olaparib and lurbinectedin in patients with advanced solid tumors. Scientific reports 2021 2 11 (1): 4433. Poveda Andres, Oaknin Ana, Romero Ignacio, Guerrero-Zotano Angel, Fariñas-Madrid Lorena, Rodriguez-Freixinos Victor, Mallol Pedro, Lopez-Reig Raquel, Lopez-Guerrero Jose Anton |
| Phase 1 study of tazemetostat in Japanese patients with relapsed or refractory B-cell lymphoma. Cancer science 2021 1 112 (3): 1123-1131. Munakata Wataru, Shirasugi Yukari, Tobinai Kensei, Onizuka Makoto, Makita Shinichi, Suzuki Rikio, Maruyama Dai, Kawai Hidetsugu, Izutsu Koji, Nakanishi Tadashi, Shiba Sari, Hojo Seichiro, Ando Kiyos |
| Larotrectinib Treatment for Patients With TRK Fusion-Positive Salivary Gland Cancers. The oncologist 2022 5 . Le Xiuning, Baik Christina, Bauman Jessica, Gilbert Jill, Brose Marcia S, Grilley-Olson Juneko E, Patil Tejas, McDermott Ray, Raez Luis E, Johnson Jennifer M, Shen Lin, Tahara Makoto, Ho Alan L, Norenberg Ricarda, Dima Laura, Brega Nicoletta, Drilon Alexander, Hong David |
| Phase Ia/Ib Study of the Selective MET Inhibitor, Savolitinib, in Patients with Advanced Solid Tumors: ?Safety, Efficacy, and Biomarkers. The oncologist 2022 4 27 (5): 342-e383. Wang Yakun, Liu Tianshu, Chen Gongyan, Gong Jifang, Bai Yuxian, Zhang Tao, Xu Nong, Liu Li, Xu Jianming, He Jianxing, Liu Yunpeng, Zhang Li, Jiang Da, Wang Mengzhao, Chang Jianhua, Li Wei, Bai Chunmei, Zhou Jinghong, Wang Jian, Ren Yongxin, Zhang Liya, Su Weiguo, Liu Baorui, Shen L |
| Intermittent MEK inhibition for the treatment of metastatic uveal melanoma. Frontiers in oncology 2022 10 12 975643. Khan Shaheer, Patel Sapna P, Shoushtari Alexander N, Ambrosini Grazia, Cremers Serge, Lee Shing, Franks Lauren, Singh-Kandah Shahnaz, Hernandez Susana, Sender Naomi, Vuolo Kristina, Nesson Alexandra, Mundi Prabhjot, Izar Benjamin, Schwartz Gary K, Carvajal Richard |
| Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase. Clinical pharmacology and therapeutics 2022 Jul . Combes François Pierre, Li Ying Fei, Hoch Matthias, Lorenzo Sebastien, Ho Yu-Yun, Sy Sherwin K |
| Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study. BMC cancer 2023 4 23 (1): 331. Hu Xingsheng, Cui Xinge, Wang Ziping, Liu Yunpeng, Luo Ying, Zhong Wei, Zhao Hui, Yao Mengxing, Jiang Da, Wang Mingxia, Chen Minjiang, Zheng Xin, Ding Lieming, Wang Yang, Yuan Xiaobin, Wu Pengxiang, Hu Bei, Han Xiaohong, Shi Yuank |
| OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. European journal of cancer (Oxford, England : 1990) 2023 3 184 39-47. Robson Mark E, Im Seock-Ah, Senkus Elzbieta, Xu Binghe, Domchek Susan M, Masuda Norikazu, Delaloge Suzette, Tung Nadine, Armstrong Anne, Dymond Mike, Fielding Anitra, Allen Allison, Conte Pierfran |
| Poziotinib in Treatment-Naïve Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-label Phase 2 Trial (Cohort 4). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2023 3 . Cornelissen Robin, Prelaj Arsela, Sun Sophie, Baik Christina, Wollner Mirjana, Haura Eric B, Mamdani Hirva, Riess Jonathan W, Cappuzzo Federico, Garassino Marina C, Heymach John V, Socinski Mark A, Leu Szu-Yun, Bhat Gajanan, Lebel Francois, Le Xiuning, |
| Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial. EClinicalMedicine 2023 10 64 102238. Si-Yang Maggie Liu, Xiao-Rong Dong, Zhen Wang, Yingying Du, Jiu-Wei Cui, Qian Chu, Bing-Fei Xu, Ming-Ying Zheng, Jia-Yi Deng, Chang Lu, Xue-Wu Wei, Yang-Si Li, Mei-Mei Zheng, Ming-Yi Yang, Jie Huang, Anna Li, Xiao-Yan Bai, Yue-Li Sun, Chong-Rui Xu, Bin-Chao Wang, Hua-Jun Chen, Jin-Ji Yang, Hong-Hong Yan, Wen-Zhao Zhong, Qing Zhou, Yi-Long |
| Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional characterization. International journal of cancer 2024 9 . Fernando Gálvez-Montosa, Giulia Peduzzi, José Manuel Sanchez-Maldonado, Rob Ter Horst, Antonio J Cabrera-Serrano, Manuel Gentiluomo, Angelica Macauda, Natalia Luque, Pelin Ünal, Francisco Javier García-Verdejo, Yang Li, José Antonio López López, Angelika Stein, H Bas Bueno-de-Mesquita, Paolo Giorgio Arcidiacono, Dalila Luciola Zanette, Christoph Kahlert, Francesco Perri, Pavel Soucek, Renata Talar-Wojnarowska, George E Theodoropoulos, Jakob R Izbicki, Hussein Tamás, Hanneke Van Laarhoven, Gennaro Nappo, Maria Chiara Petrone, Martin Lovecek, Roel C H Vermeulen, Kestutis Adamonis, Fernando Jesus Reyes-Zurita, Bernd Holleczek, Jolanta Sumskiene, Beatrice Mohelníková-Ducho?ová, Rita T Lawlor, Raffaele Pezzilli, Mateus Nobrega Aoki, Claudio Pasquali, Vitalija Petrenkiene, Daniela Basso, Stefania Bunduc, Annalisa Comandatore, Hermann Brenner, Stefano Ermini, Giuseppe Vanella, Mara R Goetz, Livia Archibugi, Maurizio Lucchesi, Faik Guntac Uzunoglu, Olivier Busch, Anna Caterina Milanetto, Marta Puzzono, Juozas Kupcinskas, Luca Morelli, Cosimo Sperti, Silvia Carrara, Gabriele Capurso, Casper H J van Eijck, Martin Oliverius, Susanne Roth, Francesca Tavano, Rudolf Kaaks, Andrea Szentesi, Ludmila Vodickova, Claudio Luchini, Ben Schöttker, Stefano Landi, Orsolya Dohan, Matteo Tacelli, William Greenhalf, Maria Gazouli, John P Neoptolemos, Giulia Martina Cavestro, Ugo Boggi, Anna Latiano, Péter Hegyi, Laura Ginocchi, Mihai G Netea, Pedro Sánchez-Rovira, Federico Canzian, Daniele Campa, Juan Sai |
| Safety, Efficacy and Biomarker Analysis of Crizotinib in MET Mutated Non-Small Cell Lung Cancer - Results from the Drug Rediscovery Protocol. Clinical cancer research : an official journal of the American Association for Cancer Research 2024 10 . Karlijn Verkerk, Tijmen J W T van der Wel, Laurien J Zeverijn, Birgit S Geurts, Ilse A C Spiekman, Gijs F de Wit, Paul Roepman, Anne M L Jansen, Vincent van der Noort, Egbert F Smit, Ann Hoeben, Lizza E L Hendriks, Michel M Van den Heuvel, Berber Piet, Gerarda J M Herder, Sayed M S Hashemi, Hans Gelderblom, Henk M W Verheul, Emile E Voest, Adrianus J de Lang |
- Page last reviewed:Feb 1, 2024
- Content source: